Trial record 19 of 37 for:    Open Studies | "Acromegaly"

Description of the Association of Signs and Symptoms Present at Acromegaly Diagnosis (ACRO-POLIS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Ipsen
Information provided by (Responsible Party):
Ipsen Identifier:
First received: November 28, 2013
Last updated: May 23, 2014
Last verified: May 2014

The purpose of this study is to describe most characteristic association of signs and symptoms present at the time of acromegaly diagnosis.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Description of the Associations of Sign-and-symptom at Acromegaly Diagnosis.

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Description of the most characteristic sign-and-symptom associations of acromegaly, collected by a patient questionnaire. [ Time Frame: At the time of patient diagnosis, up to 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Description of demographic and clinical characteristics of patients with acromegaly, collected by a patient questionnaire. [ Time Frame: At the time of patient diagnosis, up to 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 550
Study Start Date: September 2013
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Acromegalic patients


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Acromegalic patients


Inclusion Criteria:

  • Adult patient (greater than or equal to 18 years old)
  • Patient with acromegaly, diagnosed for less than 5 years

Exclusion Criteria:

  • Patient who have objected to the collection of his/her data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02012127

Contact: Ipsen Recruitment Enquiries

Toulouse, France
Sponsors and Collaborators
Study Director: Karima Menia, PhD Ipsen
  More Information

No publications provided

Responsible Party: Ipsen Identifier: NCT02012127     History of Changes
Other Study ID Numbers: 8-54-52030-266
Study First Received: November 28, 2013
Last Updated: May 23, 2014
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Signs and Symptoms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on July 20, 2014